BMS-986365 for Healthy Subjects
Trial Summary
Do I have to stop taking my current medications for this trial?
The protocol does not specify if you need to stop taking your current medications, but since the trial is for healthy subjects, you likely shouldn't be on any significant medications.
What data supports the idea that BMS-986365 for Healthy Subjects is an effective drug?
The available research does not provide any data specifically about BMS-986365, also known as CC-94676 or Gridegalutamide, being an effective treatment. The studies mentioned focus on other drugs and treatments for glioblastoma, such as DTCM-glutarimide, glufosfamide, bombesin/gastrin-releasing peptide antagonists, and cilengitide. These studies explore different approaches to treating glioblastoma, but none of them mention BMS-986365 or provide data on its effectiveness.12345
What safety data is available for BMS-986365, CC-94676, or Gridegalutamide?
Is the drug BMS-986365 a promising treatment for healthy subjects?
What is the purpose of this trial?
The purpose of this study is to evaluate the safety, tolerability, drug levels, food effects and relative bioavailability of BMS-986365 in healthy male participants.
Research Team
Bristol-Myers Squibb
Principal Investigator
Bristol-Myers Squibb
Eligibility Criteria
This trial is for healthy adult men who can participate in a study to assess the safety of a new medication. Specific eligibility criteria are not provided, but typically participants must meet certain health standards and have no conflicting medical conditions.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive single ascending doses of BMS-986365 to evaluate safety, tolerability, and pharmacokinetics
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- BMS-986365
Find a Clinic Near You
Who Is Running the Clinical Trial?
Celgene
Lead Sponsor
Jay Backstrom
Celgene
Chief Medical Officer since 2016
MD
Mark Alles
Celgene
Chief Executive Officer since 2016
Bachelor's degree from Lock Haven University of Pennsylvania